David A. SinclairPhD · Professor of Genetics, Harvard Medical School
Yes, and repeat it
What it rests onMethylation-clock research and his own biotracking practice.
Source: lifespanpodcast.com ↗
David A. SinclairPhD · Professor of Genetics, Harvard Medical School
Yes, and repeat it
What it rests onMethylation-clock research and his own biotracking practice.
Source: lifespanpodcast.com ↗
Matt KaeberleinPhD · biogerontologist
No, do not buy one
What it rests onTest-retest and validation problems with the clocks, and the absence of regulatory oversight of the consumer products.
Source: podcasters.spotify.com ↗
Both address a general adult population. The one difference that matters is timing: the Sinclair position is from 2022, when the consumer market barely existed, and the Kaeberlein position is from 2025, after it did. The three-year gap is part of the disagreement.
Both think measurement is the right instinct. Neither says track nothing. They disagree about whether this particular product measures anything.
A consumer clock with published test-retest reliability at the individual level and a prospective association with a hard outcome. Kaeberlein has separately named one test as the most promising he has seen, which is not recorded as a claim here because the source establishes the name and not his verdict; if that qualification is real it will move this question.
You do, and your call is dated, kept, and yours to change. Follow the people you already trust and what they publish turns into a short daily practice.
Free to sign up and use. We do not ask for a card.